Dr. Lal Path Labs Ltd.
LALPATHLAB · Hospitals · NSE
₹1,569
Current Market Price
Fair Value (DCF)
₹1,032
Discount to FV
-34.2%
Updated just now
YieldIQ Score
48/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
60%
ROE
22.4%
Debt/Equity
0.07
WACC
9.8%
Market Cap
₹26,194 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
33.9%
Return on capital employed
EV / EBITDA
33.8×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
29.0×
EBIT covers interest
Current Ratio
3.39×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
5.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,568.7
Bear case
Discount -149.6%
Base case
Discount -52.1%
Bull case
Discount -14.4%
Ratio Trends
LALPATHLAB · last 9 annual periods
ROE
22.4%
ROCE
33.9%
Operating Margin
—
Debt / Equity
0.07×
PE
63.9×
EV / EBITDA
29.0×
Historical Financials
LALPATHLAB · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1581 Cr | ₹2087 Cr | ₹2017 Cr | ₹2227 Cr | ₹2461 Cr | +11.7% |
| EBITDA | — | ₹613 Cr | ₹532 Cr | ₹678 Cr | ₹789 Cr | +6.5% |
| EBIT | ₹410 Cr | ₹505 Cr | ₹381 Cr | ₹535 Cr | — | +6.8% |
| PAT | ₹297 Cr | ₹345 Cr | ₹239 Cr | ₹358 Cr | ₹487 Cr | +13.2% |
| EPS (diluted) | ₹35.25 | ₹41.57 | ₹28.74 | ₹42.98 | — | +5.1% |
| CFO | ₹398 Cr | ₹447 Cr | ₹456 Cr | ₹535 Cr | ₹569 Cr | +9.3% |
| CapEx | — | ₹-476 Cr | ₹-44.6 Cr | ₹-57.4 Cr | ₹-53.9 Cr | — |
| FCF | — | ₹-29.4 Cr | ₹411 Cr | ₹478 Cr | ₹515 Cr | — |
| Total Assets | — | ₹2353 Cr | ₹2386 Cr | ₹2456 Cr | ₹2717 Cr | +3.7% |
| Total Debt | — | ₹532 Cr | ₹419 Cr | ₹247 Cr | ₹157 Cr | -26.3% |
| Shareholders' Equity | — | ₹1508 Cr | ₹1666 Cr | ₹1849 Cr | ₹2173 Cr | +9.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LALPATHLAB vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 SAILIFE SAILIFE | — | — | Pending | 8.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
25 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹50.00/sh
Last payout
2026-02-05
₹3.50
Peak payout
₹6.00
Trailing yield
0.64%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Dr. Lal Path Labs Ltd. (LALPATHLAB.NS) trades at 1568.70 vs a model fair value of 1031.69, a gap of -34.2%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of LALPATHLAB →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LALPATHLAB →
Compare
Head-to-head with peers
Compare LALPATHLAB side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LALPATHLABNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.